Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells $85,807.43 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,311 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $85,807.43. Following the sale, the chief operating officer now directly owns 173,895 shares of the company’s stock, valued at approximately $6,456,721.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Tuesday, April 23rd, Patrick John Finn sold 2,174 shares of Twist Bioscience stock. The stock was sold at an average price of $30.12, for a total value of $65,480.88.
• On Tuesday, April 2nd, Patrick John Finn sold 492 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total value of $16,108.08.

Twist Bioscience Trading Up 4.3 %

Shares of Twist Bioscience stock opened at $43.20 on Friday. The firm has a market capitalization of $2.52 billion, a P/E ratio of -12.86 and a beta of 1.64. The business has a fifty day simple moving average of $34.26 and a two-hundred day simple moving average of $31.67. Twist Bioscience Co. has a 12 month low of $11.81 and a 12 month high of $44.92.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The business had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. During the same quarter last year, the firm posted ($1.06) earnings per share. The company’s revenue for the quarter was up 25.1% on a year-over-year basis. Analysts predict that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently modified their holdings of TWST. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Twist Bioscience by 23.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,617 shares of the company’s stock valued at $316,000 after acquiring an additional 2,933 shares in the last quarter. Strs Ohio increased its holdings in shares of Twist Bioscience by 6.5% during the third quarter. Strs Ohio now owns 27,900 shares of the company’s stock valued at $565,000 after acquiring an additional 1,700 shares in the last quarter. Rockland Trust Co. increased its holdings in shares of Twist Bioscience by 29.7% during the third quarter. Rockland Trust Co. now owns 38,500 shares of the company’s stock valued at $780,000 after acquiring an additional 8,808 shares in the last quarter. TD Asset Management Inc increased its holdings in shares of Twist Bioscience by 137.7% during the third quarter. TD Asset Management Inc now owns 73,148 shares of the company’s stock valued at $1,482,000 after acquiring an additional 42,374 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Twist Bioscience by 51.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock valued at $70,000 after acquiring an additional 1,179 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages recently commented on TWST. Barclays raised their price target on Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Evercore ISI raised their price target on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Robert W. Baird raised their price target on Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Scotiabank raised their price target on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research note on Monday. Finally, The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and raised their price objective for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Twist Bioscience has a consensus rating of “Buy” and an average price target of $42.50.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.